Intra-articular Injection of (-)-Epigallocatechin 3-Gallate (EGCG) Ameliorates Cartilage Degeneration in Guinea Pigs with Spontaneous Osteoarthritis
| Autor: | Jhong You Li, Tsung Lin Cheng, Shih-Hao Huang, Sung Yen Lin, Chung-Hwan Chen, Yi Shan Lin, Shu-Chun Chuang, Chung Da Yang, Lin Kang, Hsin Yi Shen, Hsuan-Ti Huang, Cheng Jung Ho, Chi-Fen Chang, Tsung Han Yu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty senescence Physiology Clinical Biochemistry Type II collagen Osteoarthritis Matrix metalloproteinase Biochemistry Article 03 medical and health sciences 0302 clinical medicine In vivo (−)-epigallocatechin 3-gallate (EGCG) Internal medicine Medicine cartilage Molecular Biology Aggrecan biology business.industry Cartilage lcsh:RM1-950 food and beverages (-)-epigallocatechin 3-gallate (EGCG) Cell Biology medicine.disease osteoarthritis 030104 developmental biology Endocrinology medicine.anatomical_structure lcsh:Therapeutics. Pharmacology cell senescence 030220 oncology & carcinogenesis biology.protein Alkaline phosphatase Cyclooxygenase business guinea pigs |
| Zdroj: | Antioxidants, Vol 10, Iss 178, p 178 (2021) Antioxidants Volume 10 Issue 2 |
| ISSN: | 2076-3921 |
| Popis: | Osteoarthritis (OA) is the most prevalent joint disease that causes an enormous burden of disease worldwide. (-)-Epigallocatechin 3-gallate (EGCG) has been reported to reduce post-traumatic OA progression through its anti-inflammatory property. Aging is the most crucial risk factor of OA, and the majority of OA incidences are related to age and not trauma. In this study, we assess whether EGCG can ameliorate cartilage degradation in primary OA. In an in-vitro study, real-time PCR was performed to assess the expression of genes associated with human articular chondrocyte homeostasis. A spontaneously occurring OA model in guinea pigs was used to investigate the effect of EGCG in vivo. OA severity was evaluated using Safranin O staining and Osteoarthritis Research Society International (OARSI) scores, as well as by immunohistochemical (IHC) analysis to determine the protein level of type II collagen (Col II), matrix metalloproteinase 13 (MMP-13), and p16 ink4a in articular cartilage. In the in-vitro study, EGCG increased the gene expression of aggrecan and Col II and decreased the expression of interleukin-1, cyclooxygenase 2, MMP-13, alkaline phosphatase, Col X, and p16 Ink4a EGCG treatment also attenuated the degraded cartilage with a lower OARSI score. Meanwhile, IHC results showed that EGCG exerted an anti-OA effect by reducing ECM degradation, cartilage inflammation, and cell senescence with a less-immunostained Col II, MMP-13, and p16 Ink4a. In conclusion, these findings suggest that EGCG may be a potential disease-modifying OA drug for the treatment of primary OA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|